CA
SGMT icon

CHI Advisors’s Sagimet Biosciences SGMT Stock Holding History

CHI Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.07M Buy
+348,842
New +$4.64M 1.22% 19

Other funds holding SGMT

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CHI Advisors's SGMT Position: Q3 2023 in Review

CHI Advisors opened a new position in Sagimet Biosciences (SGMT) in Q3 2023: 348,842 shares worth $3.07M. The stake represents 1.22% of the portfolio and ranks #19 among its holdings.

48 funds tracked by Wall St. Rank hold SGMT as of Q3 2023.

  • CHI Advisors held 348,842 shares of Sagimet Biosciences worth $3.07M as of Q3 2023.
  • Sagimet Biosciences was a new CHI Advisors position in Q3 2023.
  • Sagimet Biosciences made up 1.22% of CHI Advisors's portfolio in Q3 2023, its #19 holding.
  • 48 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.